Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2^pos Breast Cancer

Figure 2

Trypan Blue retention maximized by dual treatment with sunitinib and Th1 cytokines. MDA-MB-468, MDA-MB-231, SKBR-3, HCC-1419, and MCF-7 cells were seeded at per mL and were left either untreated (No Rx) or treated with Th1 cytokines (5 ng/mL), sunitinib (10 μM), or sunitinib and Th1 cytokines (both) for 72 hours. Cells were harvested and stained with Trypan Blue dye, after which dye uptake was detected via its fluorescent properties via flow cytometry using a 642 nm excitation laser. (a) Histogram analysis of representative experiment for each cell line. The gated region represents the percentage of Trypan Blue-retaining (dead) cells. (b) Data represent the summary analysis of mean channel fluorescent index of treated, stained cells from at least three separate experiments per cell line. Statistical significance was determined by one-way ANOVA: MDA-MB-231 (, ), MDA-MB-468 (, ), MCF-7 (, ), HCC-1419 (, ), and SKBR-3 (, ), followed by the post hoc Tukey test. Error bars represent the standard error of the mean.

(a)

(b)